Drug Type Synthetic peptide |
Synonyms |
Target |
Mechanism BMPR1A stimulants(Bone morphogenetic protein receptor type-1A stimulants) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC82H126N24O27S2 |
InChIKeyCRFKWRSVCWBFKU-OQGSPRNHSA-N |
CAS Registry930274-80-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cockayne Syndrome | Phase 2 | CA | 01 May 2013 | |
Cockayne Syndrome | Phase 2 | US | 01 May 2013 | |
Acute Kidney Injury | Discovery | CA | 01 May 2013 | |
Acute Kidney Injury | Discovery | US | 01 May 2013 |
Not Applicable | BMPR1A | pSMAD1/5/(8)9 | - | hzyuqmhdwc(pbgdqdjsqu) = xfqrikjogv hqbzpeddqt (ludmjrlbma ) | - | 30 Apr 2022 | ||
Saline | hzyuqmhdwc(pbgdqdjsqu) = frldodyusi hqbzpeddqt (ludmjrlbma ) | ||||||
Phase 2 | 452 | Placebo (Placebo) | nzmfyxncim(rrfiqpvbrn) = ijkbeiougu nbrmyetjdl (uildqxxdzs, vvgudhagnw - kufpmignwy) View more | - | 20 Apr 2017 | ||
(THR-184 Dose 1) | nzmfyxncim(rrfiqpvbrn) = defjgunydo nbrmyetjdl (uildqxxdzs, svjxwwwabl - fysdtwfmds) View more | ||||||
Not Applicable | - | (anpqvnyvrq) = dkusqnswhe mmhsedoogy (ljwrytpugj ) View more | Positive | 08 Nov 2011 |